Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The FDA's written response to the company's Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population. Emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The HARMONIC trial is evaluating LP-300, a cisplatin/ethacraplatin analog, in never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor (TKI) treatment. Lantern Pharma's precision oncology approach leverages its proprietary RADR platform, which uses artificial intelligence and machine learning to transform cancer therapy development. The company's pipeline also includes LP-184 (acylfulvene) and LP-284, a TC-NER targeting compound for hematologic and solid tumors.
Lantern Pharma has also commercialized withZeta.ai, a multi-agentic AI co-scientist platform now available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The FDA's support for the protocol amendments is a significant step for Lantern Pharma as it advances LP-300 in a specific patient population with high unmet medical need. Never-smokers with NSCLC, particularly those with EGFR exon 21 L858R mutations, often have limited options after TKI failure. LP-300's potential to provide benefit in combination with chemotherapy could address a critical gap in treatment.
Lantern Pharma continues to develop its pipeline, including LP-184 for pediatric CNS cancers through Starlight Therapeutics, its wholly owned CNS-focused subsidiary. The company's AI-driven approach aims to accelerate drug development and improve outcomes for cancer patients.
